EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions

Shubhasmita Mohapatra, Adrian Guerrero, Neha Rahman iD, Khondoker Takia Zaman, Jing Wu, Callistus Onyeagba, Chanyue Hu iD, Matteo Pellegrini iD, Jayaram Vankudoth, Seiya Kitamura iD, Lauren O'Donnell iD, Youssef Zaim Wadghiri iD und 1 weitere

Cells · 2025

DOI: 10.3390/cells14211703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Shubhasmita Mohapatra und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA. Hauptthemen laut MEDLINE: Glioblastoma, Paclitaxel, Brain Neoplasms, Autoimmunity. Die Arbeit nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NCI, NYU Grossman School of Medicine Preclinical Imaging Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reprogramming of macrophages into the inflammatory state (also known as M1) is currently considered as an effective way of eliminating cancer cells, but systemic deployment of this strategy is likely to induce dangerous autoimmune reactions. Consequently, converting immunosuppressive M2-type macrophages into M1 systemically is not a safe and effective therapeutic approach against cancer. Through cleavable covalent linking of curcumin to the chemotherapeutic agent Paclitaxel (Taxol), we have created a novel prodrug (STO-1) that, upon intravenous delivery, selectively reprograms tumor-associated microglia and macrophages (TAMs) and eliminates glioblastoma (GBM) without triggering autoimmunity. Demonstrating its therapeutic efficacy, prolonged treatment of six orthotopic GBM-bearing mice with STO-1 resulted in 67% long-term survival, with three surviving mice exhibiting complete tumor clearance and one displaying minimal residual disease, as confirmed by high-resolution ex vivo T2-weighted MRI 85 days after tumor inoculation. In contrast, the vehicle-treated mice displayed extensive intracranial tumors with edema and hemorrhage. Mechanistically, scRNA-seq analysis indicated induction of multiple M1-associated transcripts (ccrl2, cxcl9, ccr2, ccl5) consistent with robust TAMs reprogramming. In striking contrast to the M2⟶M1 reprogramming of TAMs, M1-type macrophages were suppressed in the spleens of STO-1-treated cancer-free mice. Therefore, STO-1 induces selective anti-tumor immunity and GBM elimination without triggering systemic autoimmune reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaPaclitaxelBrain NeoplasmsAutoimmunityAnimalsMiceHumansMacrophagesCell Line, TumorMice, Inbred C57BLMicrogliaFemaleProdrugs

Stichwörter der Autor:innen

Arginase 1GBMSTAT1autoimmunitychemotherapeuticiNOSimmunotherapy

Substanzen

PaclitaxelProdrugs

Autor:innen und Institutionen

  • Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.
  • Center for Developmental Neuroscience, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.
  • Bernard and Irene Schwartz Center for Biomedical Imaging, and Center for Advanced Imaging Innovation and Research and Preclinical Imaging, Division for Advanced Research Technologies, Department of Radiology, New York U…
  • CUNY Doctoral Program in Biochemistry, New York, NY 10016, USA.
  • Hunter College (CUNY), New York, NY 10065, USA.
  • UCLA Molecular, Cellular & Developmental Biology, Los Angeles, CA 90095, USA.

ORCID-Profile: Neha Rahman, Chanyue Hu, Matteo Pellegrini, Seiya Kitamura, Lauren O'Donnell, Youssef Zaim Wadghiri, Probal Banerjee

Förderung

  • NCI NIH HHS
  • NCI
  • NYU Grossman School of Medicine Preclinical Imaging Laboratory
  • Laura and Isaac Perlmutter Cancer Center Support Grant
  • NIBIB Biomedical Technology Resource Center

Zitieren

APA

Mohapatra, S., Guerrero, A., Rahman, N., Zaman, K. T., Wu, J., Onyeagba, C., Hu, C., Pellegrini, M., Vankudoth, J., Kitamura, S., O'Donnell, L., Wadghiri, Y. Z., & Banerjee, P. (2025). Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions. Cells. https://doi.org/10.3390/cells14211703

Vancouver

Mohapatra S, Guerrero A, Rahman N, Zaman KT, Wu J, Onyeagba C, et al. Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions. Cells. 2025. doi:10.3390/cells14211703

BibTeX
@article{Mohapatra2025,
  author = {Mohapatra, Shubhasmita and Guerrero, Adrian and Rahman, Neha and Zaman, Khondoker Takia and Wu, Jing and Onyeagba, Callistus and Hu, Chanyue and Pellegrini, Matteo and Vankudoth, Jayaram and Kitamura, Seiya and O'Donnell, Lauren and Wadghiri, Youssef Zaim and Banerjee, Probal},
  title = {Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14211703}
}
Kostenlos starten →